https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47693 Wed 25 Jan 2023 08:42:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46698 Wed 13 Mar 2024 08:07:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15668 Wed 11 Apr 2018 16:26:48 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15194 Wed 11 Apr 2018 15:37:49 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24920 3 care episodes (median 2); 35% stayed a total of >30 days in hospital (median 17); 42% were admitted to 2 or more different hospitals. Twelve percent of decedents spent time in an ICU with median 3 days. In the metropolitan area, 80% of decedents presented to an ED and 18% had >3 presentations. Overall 55% died in a hospital or inpatient hospice. Although we could not quantify the extent and type of palliative care, 24% had mention of "palliative care" in their records. The very elderly and those dying from diseases of the circulatory system or living in the least disadvantaged areas generally had lower hospital service use. Conclusions: These population-wide health data collections give a highly informative description of NSW hospital-based end-of-life service utilisation. Use of hospital-based services during the last year of life was common, with substantial variation across sociodemographic groups, especially defined by age, cause of death and socioeconomic classification of the decedents' place of residence. Further research is now needed to identify the contributors to these findings. Gaps in data collection were identified - particularly for palliative care and patient-reported outcomes. Addressing these gaps should facilitate improved monitoring and assessment of service use and care.]]> Wed 11 Apr 2018 15:25:07 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21261 Wed 11 Apr 2018 12:22:40 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48997 35 cigarettes/day. Lung cancer risk was lower with quitting at any age but remained higher than never-smokers for quitters aged >25y. By age 80y, an estimated 48.3% of current-smokers (41.1% never-smokers) will develop cancer, and 14% will develop lung cancer, including 7.7% currently smoking 1-5 cigarettes/day and 26.4% for >35 cigarettes/day (1.0% never-smokers). Cancer risk for Australian smokers is significant, even for 'light' smokers. These contemporary estimates underpin the need for continued investment in strategies to prevent smoking uptake and facilitate cessation, which remain key to reducing cancer morbidity and mortality worldwide.]]> Wed 03 May 2023 12:03:16 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50708 Wed 02 Aug 2023 15:00:51 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35066 Thu 13 Jan 2022 10:28:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36303 80%) for six of the 12 most common cancer types: breast, colorectum, kidney, lung, pancreas and uterus. The available hospital data covered more recent time periods. We have since obtained more recent cancer registry data, allowing us to further test the validity of hospital diagnosis records in identifying incident cases. Results: The more recent hospital diagnosis data were valid for identifying incident cases for the six cancer types, with sensitivities 81-94% and PPVs 86-96%. However, 2-10% of cases were identified >3 months after the registry's diagnosis date and detailed clinical cancer information was unavailable. The level of identification was generally higher for cases aged <80 years, those with known disease stage and cases living in higher socioeconomic areas. The inclusion of death records increased sensitivity for some cancer types, but requires caution due to potential false-positive cases. This study validates the use of hospital diagnosis records for identifying incident cancer cases.]]> Thu 13 Jan 2022 10:28:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14678 Sat 24 Mar 2018 08:19:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51405 Mon 04 Sep 2023 14:53:07 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40089 p<0.0001), smoking (p<0.0001) and unknown stage (p = 0.002). There was no evidence of differences by year of diagnosis or sex (both p>0.50). For 465 cases diagnosed 2014–2015, 29% had subsidised molecular testing for targeted therapy/immunotherapy and 4% had subsidised targeted therapies. Conclusions: Lung cancer healthcare costs are strongly associated with survival-related factors. Costs appeared stable over the period 2006–2013. This study provides a framework for evaluating the health/economic impact of introducing lung cancer screening and other interventions in Australia.]]> Fri 15 Jul 2022 10:04:25 AEST ]]>